SAN DIEGO, June 20, 2025 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Tempus AI, Inc. (NASDAQ: TEM) common stock between August 6, 2024 and May 27, 2025.  Tempus purports to be provide Artificial Intelligence ("AI") enabled precision medicine solutions.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The Allegations: Robbins LLP is Investigating Allegations th ...

Group 1 - A class action has been filed against Reddit, Inc. on behalf of investors who purchased securities between October 29, 2024, and May 20, 2025 [1] - The allegations include that Reddit misled investors about reduced user traffic due to changes in Google Search's algorithm and features, which led to a significant decline in traffic to the Reddit website [2] - The complaint states that the defendants were aware that increased search queries for "Reddit" were due to users finding answers directly on Google, rather than intending to visit Reddit, which contributed to the misleading public statements [2] Group 2 - Shareholders may be eligible to participate in the class action and can contact Robbins LLP for more information on serving as lead plaintiff [3] - The representation in the class action is on a contingency fee basis, meaning shareholders will not incur fees or expenses [4] - Robbins LLP has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4]

Reiterate Commitment to Fight for Liquidity and Transparency Against Entrenched Incumbents Set Record Straight on Ionic’s Most Recent Misleading Statements Urge Their Fellow Stockholders to Learn More About Their Plan for Change at www.ionicvote.com SAN FRANCISCO, June 17, 2025 (GLOBE NEWSWIRE) -- Tony Vejseli, Chris Villinger, and Brett Perry (the “Concerned Stockholders”), stockholders of Ionic Digital Inc. (“Ionic” or the “Company”), today issued a public letter to their fellow stockholders announcing th ...

My next guest has been turning to the US ENTP names lately and two of her top picks are up more than 5% over the past week. Let's bring in Victoria Green, G Squared Private Wealth CIO and a CNBC contributor. Victoria, let's start with why.Um, you know, a a lot of times it's very hard to predict uh what's going to happen with these international developments. So, why did you jump into the ENTP space and where did you put your money. Yeah, sure.If you're saying, hey, this conflict may continue to grow. it cou ...

Key Takeaways TTEK is seeing strong orders across the U.S. and international sectors, boosting key segment revenues. Recent acquisitions expand TTEK's reach in the water, energy, automation and federal IT markets. TTEK expects FY25 revenues of $4.400-$4.765B, up from $4.322B in FY24.Tetra Tech, Inc. (TTEK) is well-positioned for growth courtesy of strength across its end markets, strategic acquisitions and focus on operational excellence. The company remains focused on investing in growth opportunities an ...

Activist investor Barington Capital Group joins a growing chorus of dissatisfied Victoria's Secret VSCO shareholders.What Happened: The firm now holds more than 1% of the lingerie retailer's stock and plans to increase its position.Its campaign follows a sharp stock decline—more than 50% year-to-date. Victoria's Secret's market value slashed to about $1.5 billion. That's a steep drop from the $6.5 billion valuation it commanded after its 2021 split from Bath & Body Works Inc. BBWI.Also Read: Victoria’s Secr ...

TORONTO, June 13, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”), a pharmaceutical company specialized in precision-based cannabinoids, today announced that leading independent proxy voting and corporate governance advisory firm Glass, Lewis & Co. LLC (“Glass Lewis”) published a report on June 12, 2025 recommending that MediPharm shareholders vote the GREEN Proxy or voting instruction form FOR the Company’s nominees for the Board of Directo ...

Core Points - The Company is convening an extraordinary shareholders' meeting on July 2, 2025, at 2:00 p.m. CET, with an option for remote participation via video conference [2][3] - The agenda includes a proposal to amend the articles of association to allow shareholders holding at least 5% of outstanding shares for three years to nominate directors [5][6] - Shareholders must register by June 18, 2025, and notify the Company of their intention to participate by June 26, 2025 [13][14] Meeting Details - The meeting will be held at the Company's seat, with video conference facilities for remote attendees [2][3] - Attendance registration will begin at 1:45 p.m. CET on the day of the meeting [4] - Voting can be conducted by mail or by proxy, with specific forms required for these processes [17][18] Voting and Participation - Each share entitles the holder to one vote, and decisions require a 75% majority for certain agenda items [28][29] - Shareholders wishing to ask questions must submit them by June 26, 2025, and answers will be provided during the meeting [24] - Documentation related to the meeting is available on the Company's website and can be requested via email [25]

Group 1 - A class action has been filed on behalf of investors who purchased PepGen Inc. (NASDAQ:PEPG) securities between March 7, 2024, and March 3, 2025 [1] - PepGen is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases, with its lead product candidate being PGN-EDO51 for Duchenne muscular dystrophy (DMD) [1] - Allegations against PepGen include misleading investors about the effectiveness and safety of PGN-EDO51, deficiencies in the CONNECT2 study, and overstated clinical and commercial prospects [2] Group 2 - On January 29, 2025, PepGen reported safety concerns in the CONNECT1 study and FDA concerns regarding the CONNECT2 study, leading to a stock price drop of $0.40 per share (21.74%) [3] - Following a press release on March 4, 2025, announcing a voluntary pause of the CONNECT2 study, PepGen's stock price fell by $0.53 per share (18.86%) [4] - Shareholders interested in participating in the class action must file a motion for lead plaintiff by August 8, 2025 [5]

Announcement about a change in a major shareholder’s shareholding, cf. S.31 of the Danish Capital Market Act. In continuation of the capital reduction implemented by cancellation of 2,765,118 own shares of a nominal value of DKK 10 as described in Corporate Announcement No. 26 of 12 June 2025, we hereby announce in accordance with S.31 of the Danish Capital Market Act that Jyske Bank A/S as at 12 June 2022 directly and indirectly held 998,572 shares of a nominal value of DKK 10 of Jyske Bank A/S correspond ...